Dark

Check out our Level2View

BPSR
Biotech Products Services and Research, Inc. Common Stock
stock OTC

Inactive

Nov 5, 2021

0.0600USD+22.449%(+0.0110)3,096,260

Pre-market

0.00USD-100.000%(-0.05)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Nov 5, 2021

12:44PM EDT FINRA Approves Marketplace Name Change to Organicell Regenerative Medicine, PR Newswire

May 4, 2021

07:50AM EDT Organicell Says Begins Up-Listing Process On NASDAQ Exchange Benzinga

Nov 18, 2020

09:12AM EST CORRECTING and REPLACING Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin(tm) for Treatment of COVID-19 Business Wire

07:22AM EST Organicell Announces Additional Site For Phase I/II Trial Of Zofin For Treatment Of COVID-19 RTTNews

07:00AM EST Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin(tm) for Treatment of COVID-19 Business Wire

Oct 20, 2020

07:00AM EDT Organicell Partners with Regenerative Care Network to Study GlobeNewswire Inc

Sep 29, 2020

07:00AM EDT FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin(tm) Business Wire

Aug 18, 2020

07:00AM EDT Organicell Phase I/II Clinical Trial Update GlobeNewswire Inc

Aug 13, 2020

07:00AM EDT Organicell Completes Capital Raise from Retrograde GlobeNewswire Inc

Aug 6, 2020

07:00AM EDT Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs)for treating mild to moderate respiratory distress due to COVID-19. GlobeNewswire Inc

Share